Gliomas are brain tumors characterized by an immunosuppressive microenvironment.
Immunostimulatory agonistic CD40 antibodies (αCD40) are in clinical development for solid …

Antiangiogenic treatment targeting the vascular endothelial growth factor (VEGF) signaling
pathway is in clinical use, but its effect on vascular function and the tumor microenvironment …

Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is
associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T …

Boosting natural immunity against malignant cells has had a major breakthrough in clinical
cancer therapy. This is mainly due to the successful development of immune checkpoint …

Glioblastoma is an aggressive brain tumor characterized by an abnormal blood vasculature
that is hyperpermeable. Here, we report a novel role for CD93 in regulating angiogenesis in …

Conditional knockout of PDGFB in platelets demonstrates its previously unknown role in the
maintenance of tumor vascular integrity and host protection against metastasis. …

Purpose Oligodendrogliomas are heterogeneous tumors in terms of imaging appearance,
and a deeper understanding of the histopathological tumor characteristics in correlation to …

CD40-stimulating immunotherapy can elicit potent anti-tumor responses by activating dendritic
cells and enhancing T-cell priming. Tumor vessels orchestrate T-cell recruitment during …

CD40-activating immunotherapy has potent antitumor effects due to its ability to activate
dendritic cells and induce cytotoxic T-cell responses. However, its efficacy is limited by …

Background Tumor vessels in glioma are molecularly and functionally abnormal, contributing
to treatment resistance. Proteins differentially expressed in glioma vessels can change …